Drug Discovery World

MARCH 12, 2024

To this end, a grant of $3 million offered in the Bio Studio programme to mature a technology for ‘platform-market-fit’ is a unique opportunity for translational projects. RA: What advantages does a plant-based approach bring to drug development? 25% of approved drugs having a halogen incorporated.

Small Molecule 147

Small Molecule Synthetic Chemistry Production Molecular Biology 147

Drug Discovery World

OCTOBER 4, 2022

New York-based Oligomerix is an emerging clinical-stage biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterised by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) to Alzheimer’s disease (AD).

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Discovery World

DECEMBER 21, 2023

Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker. DDW Multimedia Editor Megan Thomas explored three trends in the market.

FDA Approval 147

FDA Approval Therapies Small Molecule Clinical Trials 147

Drug Discovery World

FEBRUARY 13, 2024

Often this can be drug approvals, exciting research into hard-to-treat indications, or even regulatory updates that enable players within the sector to utilise the latest technologies and drive therapies to market faster, ultimately benefitting patients. Progress isn’t stagnant though.

Small Molecule 147

Small Molecule Drugs Therapies Pharmaceutical Companies 147

Drug Discovery World

FEBRUARY 22, 2023

More than 20% of new drugs are now coming from small innovative organisations and this percentage is increasing exponentially as these small organisations adopt this new technology. We have also worked with companies that have introduced the drug to emerging markets at a lower price.

Small Molecule 130

Small Molecule Drug Development Drugs Packaging 130

Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. Cavlan explains that “they are brilliant at developing and bringing new drugs to market.”

Drug Development 98

Drug Development Drugs Pharmaceutical Companies Clinical Development 98

Drug Discovery World

AUGUST 14, 2023

Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. In cancer, PGE2 acts in the tumour microenvironment to trigger cancer cells to evade the immune system.

Trials 130

Trials Small Molecule Pharmacokinetics Clinical Trials 130

Drug Discovery World

DECEMBER 26, 2023

Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis’ hereditary angioedema (HAE) drug candidate donidalorsen in Europe.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

Drug Discovery World

FEBRUARY 27, 2023

What advice do you have for other start-ups hoping to launch into this market? For founders planning to launch their start-ups, specifically drug developers, there needs to be sound, foundational science with promising data that will enable you to push further down the drug discovery pipeline.

RNA 130

RNA Science Small Molecule Engineering 130

PPD

OCTOBER 18, 2023

As exponential growth and global expansion continue in both the biotech and pharmaceutical industries, it is critical for drug development companies to partner with good manufacturing practices (GMP) / chemistry manufacturing and controls (CMC) contract labs to conduct analyses of a range of small molecules and biologics and drive therapies forward (..)

Laboratories 52

Laboratories Assay Development Small Molecule Packaging 52

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Small molecule GLP1s?

Small Molecule 140

Small Molecule Trials Therapies Disease 140

LifeSciVC

AUGUST 5, 2024

We are constantly reminded how we are in the midst of an artificial intelligence revolution of the drug development process which promises to completely transform how we develop drugs with increases in productivity of an order of magnitude or more. a company with the strongest pipeline in the entire industry.”

Molecular Biology 90

Molecular Biology Production Small Molecule Drug Development 90

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. The UK is additionally able to serve the US market with excellent international cultural and linguistic links.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

DECEMBER 8, 2023

Investments in AI and related technologies are driving this seismic shift where modest improvements in early-stage drug development success rates enabled by AI and machine learning could lead to an additional 50 novel therapies over 10 year s, a more than $50 billion opportunity.

Therapies 162

Therapies Clinical Trials Small Molecule Production 162

Drug Discovery World

SEPTEMBER 26, 2022

A report by the medical charity LifeArc 1 puts the timeframe for a therapy brought to market through repurposing methods at anywhere from one to three years. This is a stark contrast to the often decade-long projects that pharmaceutical companies undertake to bring a drug to market. Volume 23 – Issue 4, Fall 2022. References .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

PPD

JUNE 27, 2024

In recent years, AA has followed in the footsteps of other dermatology indications — including psoriasis and atopic dermatitis — with growing research and clinical studies focusing on small molecules with broad cellular effects (JAK and PDE4 inhibitors) and cytokine-specific molecules antagonists (IL-23, Th2 and IL17) to treat the condition.

Treatment 52

Treatment Clinical Trials Small Molecule Clinical Research 52

Drug Target Review

JUNE 19, 2024

Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy. Just like small molecules and antibodies, cell therapies are changing how we treat patients. from May 2017 until December 2022.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

The Pharma Data

JANUARY 25, 2021

–( BUSINESS WIRE )– Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. 26, 2021 13:00 UTC. FREDERICK, Md.–( About VLX-1005.

FDA 52

FDA Small Molecule FDA Approval Drugs 52

PerkinElmer

JANUARY 21, 2021

Using drugs that are already on the market was the quickest path forward to evaluate these compounds and possibly help patients now because novel drug development typically takes years. Scientists needed to evaluate the field of potential drugs-and fast. COVID-19 is a difficult disease to understand and treat.

Treatment 52

Treatment Small Molecule Drugs Virus 52

The Pharma Data

JUNE 28, 2021

Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

The Premier Consulting Blog

JULY 9, 2023

During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. Degradants are impurities arising from the degradation of the drug substance or a reaction with an excipient and/or the immediate container.)

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52

Drug Target Review

MARCH 1, 2024

About the author Dr Christopher Haqq Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Dr Haqq is an oncologist with more than two decades of experience in drug development working across cell therapy, small molecule and biologics in large and small biotech settings.

Immune Response 105

Immune Response Vaccine Therapies Small Molecule 105

Creative Biolabs

JUNE 29, 2023

At present, a large number of G protein-coupled receptor-targeted drugs have been marketed, and a large number of drugs are under development. GPCR is the most valuable target for drug development, and more drugs will be used to treat various diseases in the future.

Therapies 52

Therapies Small Molecule Research Drug Development 52

Drug Discovery World

APRIL 25, 2023

Dawn Bio which is a drug discovery platform based on human embryo models for drug development for women’s reproductive health. This funding follows a £360K ($435K) Biomedical Catalyst grant from Innovate UK, awarded to FAB early in 2022 to develop its technology as a treatment for chronic wounds. billion by 2030.

Science 130

Science Small Molecule Disease Government 130

The Pharma Data

NOVEMBER 26, 2020

This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. ” Prof. ” Prof. Finnish time. About Nanoform. For more information please visit [link].

Small Molecule 52

Small Molecule Clinical Trials Marketing Pharmaceuticals 52

Drug Discovery World

SEPTEMBER 9, 2024

AI-driven drug discovery is increasingly commonplace, with companies actively exploring hundreds of AI-driven candidates in the discovery and early clinical stages 1. However, no AI-discovered or designed drugs have yet reached the market.

Drugs 162

Drugs Bioinformatics Computational Chemistry International 162

Sygnature Discovery

OCTOBER 10, 2023

With a specific interest in neuroscience, the company specializes in the development of in vitro test model systems using neuronal and neuroinflammatory cells and was first to market in the manufacturing of functional iPSC-derived microglia at scale.

Small Molecule 52

Small Molecule Drugs Disease Clinical Trials 52

Drug Discovery World

AUGUST 5, 2022

Ian Hollingsworth, Associate Director of product development at Boyds, the global drug development consultancy, explains the benefits to the drug development lifecycle of building strong partnerships with external consultants, and when and how to get the best from them. Why sponsors use external consultants.

Drug Development 130

Drug Development Drugs Pharma Companies International 130

Drug Discovery World

NOVEMBER 17, 2022

SkyQuest Technology recently released a report: Global Synthetic Biology Market Insights, which highlights the sector’s value and potential. It shows that the synthetic biology market was valued at US$9.5 These factors can significantly contribute to the growth of the synthetic biology market, it adds. . billion by 2027. .

Engineering 130

Engineering Molecular Biology Synthetic Chemistry DNA 130

The Pharma Data

MARCH 28, 2022

Dupixent is now a market leader and more than 400,000 patients with certain types of atopic dermatitis (AD), asthma and chronic rhinosinusitis with nasal polyposis have been treated globally. Two complementary candidates for COPD , developed in collaboration with Regeneron, targeting distinct subpopulations.

Small Molecule 52

Small Molecule Clinical Development Disease Science 52

Drug Discovery World

DECEMBER 7, 2022

By Dr Natalia Dadivanyan , Segment Marketing Manager, Malvern Panalytical . Small molecules can face big challenges . Despite the emergence of, and excitement around, advanced therapeutic modalities, traditional small molecule pharmaceuticals still occupy a significant and steadily growing share of the market.

Small Molecule 130

Small Molecule Pharmaceuticals Pharmaceutical Companies Drug Development 130

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Science 100

Science Drugs FDA Engineering 100

Drug Discovery World

APRIL 12, 2023

This paid-for advertorial by CN Bio appeared in DDW Volume 24 – Issue 2, Spring 2023 Despite advancements, the drug development process remains inefficient. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130

Drug Discovery World

JANUARY 20, 2023

This paid-for advertorial by CN Bio appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Despite advancements, the drug development process remains inefficient. Existing in vivo and in vitro models aren’t up to the challenge Preclinical tools exist for the evaluation and screening of potential drug candidates.

Drug Development 130

Drug Development Drugs Small Molecule Immune Response 130

Drug Target Review

NOVEMBER 22, 2023

Whilst TGF-β is an attractive target for cancer therapy because of its critical role in promoting tumor aggressiveness, immune escape and resistance to therapy, activation of alternative resistance pathways has hindered drug development attempts in the past. Pancreatic cancer is a very difficult cancer to treat.

Licensing 52

Licensing Licensing Small Molecule Therapies 52

Drug Discovery World

JANUARY 24, 2024

Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. MT: Your appointment comes as Fibrocor seeks to advance two drug candidates – exquisitely specific kinase inhibitor small molecules (FIB992 and FIB991) for rare indications into the clinic. PW: FIB992 is our lead compound.

Small Molecule 147

Small Molecule Research Pharma Companies Disease 147

The Pharma Data

OCTOBER 25, 2020

Vatiquinone, developed from PTC’s Bio-e platform, is an investigational oral small molecule that inhibits 15-Lipoxygenase, a key enzyme that regulates oxidative stress and inflammation response pathways underpinning many neurological disease pathologies, including epilepsy. About PTC Therapeutics, Inc.

Clinical Trials 52

Clinical Trials Trials Small Molecule Regulations 52